Abstract:
본 발명은 인간 순수 만능줄기세포 (human naive pluripotent stem cell)에 특이적으로 결합하는 단일클론항체 및 이를 생산하는 하이브리도마에 관한 것으로서, 구체적으로는 인간 순수만능줄기세포에는 결합하고 인간 준 만능줄기세포에는 결합하지 않거나 결합력이 현저히 약한 단일클론항체 N16-F2, 상기 단일클론항체를 생산하는 하이브리도마 N16-F2, 상기 단일클론항체 N16-F2를 포함하는 검정키트 및 인간 만능줄기세포 제거용 조성물에 관한 것이다.
Abstract:
본 발명은 인간 순수 만능줄기세포 (human naive pluripotent stem cell)에 특이적으로 결합하는 단일클론항체 및 이를 생산하는 하이브리도마에 관한 것으로서, 구체적으로는 인간 순수만능줄기세포에는 결합하고 인간 준 만능줄기세포에는 결합하지 않거나 결합력이 현저히 약한 단일클론항체 N16-F2, 상기 단일클론항체를 생산하는 하이브리도마 N16-F2, 상기 단일클론항체 N16-F2를 포함하는 검정키트 및 인간 만능줄기세포 제거용 조성물에 관한 것이다.
Abstract:
The present invention relates to a composition comprising monoclonal antibody 57-C11 as an active ingredient for preventing or treating cancer diseases. More particularly, the present invention relates to a composition comprising monoclonal antibody 57-C11 specifically binding to an undifferentiated human embryonic stem cell, wherein monoclonal antibody 57-C11 inhibits growth of human embryonic stem cells or embryonic cancer cells and inhibits growth of skin cancer cells, small cell lung cancer cells, and neuroblastoma, which express 57-C11 antigen on a surface thereof, among various cancer cells. More specifically, monoclonal antibody 57-C11 specifically recognizes E1B-AP5 protein on a surface of an undifferentiated human embryonic stem cell. By recognizing E1B-AP5, the present invention can be usefully applied to inhibition of growth of human embryonic stem cells and embryonic cancer cells, as well as, growth of skin cancer cells, small cell lung cancer cells, and neuroblastoma.
Abstract:
PURPOSE: A monoclonal antibody which specifically binds to an undifferentiated human embryonic stem cell and a hybridoma producing the same are provided to specifically recognize cell surface protein of the undifferentiated human embryonic stem cell and remove undifferentiated embryonic stem cell during cell therapy. CONSTITUTION: A method for preparing monoclonal antibody which is specific to an undifferentiated human embryonic stem cell comprises: a step of injecting differentiated human embryonic stem cells to one side of animal body; a step of injecting undifferentiated human embryonic stem cells to the other side of animal body to induce immunity; and a step of removing antibodies to common surface antigens which exist in both differentiated and undifferentiated embryonic stem cell from lymph node of the other side of the animal body.